Articles & Video
Biopharma Partnering and Financing Trends, H1 2020
With the help of Biomedtracker, analysts at Pharma Intelligence have taken a deep dive into the worldwide biopharma industry partnership and financial dealmaking during the first halves of 2019 and 2020. What they found is astounding and inside the new white paper.
Biotech Startups: How to Succeed in a COVID-19 World
Taking a biotech company from concept, through clinical trials, and ultimately to market requires a perfect storm of good science, a sound investment, and the right management. This ebook is here to guide startups through this journey.
Interview: Promoting prosperity in the life science sectors of China and the UK
In this exclusive interview, Her Majesty’s Trade Commissioner for China at the Department for International Trade, John Edwards, discusses how China’s healthcare and life sciences markets are growing rapidly and are driven by increased demand and changes to regulations, plus much more.
Interview: Importance of diversity and partnering in global life sciences
ATLATL Innovation Cluster (IC) in the heart of Zhangjiang Pharma Valley. Its Founder and CEO, Dr. P.C. Zhu, designed it to be a launchpad for high-potential life sciences in China. In this interview with EBD Group he discusses the opportunities ATLATL provides and the importance of partnering in the life science industry.
Video Interview - Johnson & Johnson’s approach to external innovation
William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation gives an exclusive interview to Lucie Ellis, Executive Editor of In Vivo, Pharma Intelligence, ahead of ChinaBio® Partnering Forum Digital.
Interview – J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies
Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the importance of collaborations and much more in this exclusive interview with EBD Group.
REPORT: State of China Life Science - 2020 H1
Download this new exclusive ChinaBio® report with in-depth analysis of investment and partnering activity in China for 2020 H1 to discover the factors driving China life science investment. Learn how VC, IPO, and Partnering have rebounded despite COVID-19, but how M&A continues to slump.
Top Biotech Deals in China
Discover the deals transforming China biotech! More than $12 billion in biopharma financing, alliances, IPOs, and new funds have been generated so far this year in China. Learn the details of these deals when you read this new free infographic.
Pharma R&D Annual Review 2020
The researchers and analysts at Pharma Intelligence have taken the guess work out of figuring out how pharmaceutical research and development has progressed over the past few years and what you can expect in 2020. Pharma R&D Annual Review 2020 condenses the thorough analysis of all drugs in development by pharmaceutical companies, from those at the preclinical stage, through the various stages of clinical testing and regulatory approval, and up to and including launch.
China's Challenges and Opportunities in the Wake of COVID-19
Discover how pharma companies in China are collaborating like never before to keep the supply chain from breaking, as well as asking the government to help address a flurry of issues laid bare by the public health crisis.
Interview- Roche’s approach to drug discovery, innovation and meeting patients' needs
James Sabry, Global Head of Roche Pharma Partnering, discusses Roche’s approach to discovering scientific breakthroughs, accelerating innovative research, collaborating with stakeholders, and meeting unmet medical needs in China and around the world.
Biopharma and Tech Innovators – Summer 2020
Download Xconomy and EBD Group’s new special report, Biopharma and Tech Innovators – Summer 2020, to learn more about the cutting-edge companies behind these innovations that are disrupting the sector and revolutionizing the healthcare landscape.
Latest Cancer Developments and Trends
Discover the latest trends and advancements in cancer treatment in this new article pack from Informa Pharma Intelligence. Inside this downloadable article pack you will discover what is driving oncology dealmaking in 2020.
Containing Coronavirus Through Innovation and Investment: An Xconomy Special Report
This report contains ideas, innovation, and experience from some of the major players at the forefront of efforts in combatting COVID-19. The exclusive articles were captured from the BIO-Europe Spring® event and are accompanied by some of the most pertinent stories from B2B publications Xconomy and Bioprocess Insider.
A Backstage View Of Roche’s Recent Collaborations
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
Oncology Needs Combo Therapies & More Data Analysis, Says BIO-Europe Spring Panel
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference.
Servier BioInnovation: A global innovation engine to boost early-stage R&D through partnering
In today’s rapidly changing and ever-evolving global biomedical innovation ecosystem, collaboration and partnerships are key to R&D success to ensure the development of a sustainable pipeline of innovative new medicines.
New approaches to drug discovery and development enabled by platform success
Relatively small Enabling Technology Platform companies are changing the future for patients, drug discovery scientists, therapeutic scientists, developers, new therapy approach scientists, plus payers. Sometimes, it is important to remind oneself that biotech is working for the good of the worldwide healthcare industry and not just our local markets.
The 2020 Outlook for Europe
Discover insights and gain helpful advice in this curated article pack from Informa Pharma Intelligence on biotech, regulations, pharma, and financial investment in Europe and the United Kingdom.
Paris Region to lead the field in personalized medicine and biopharma 3.0
Medicen Paris Region is thrilled to host the 2020 edition of BIO-Europe Spring following the great success of the 2015 conference here. The Paris Region is a worldwide hub when it comes to healthcare innovation, and the very first European region when it comes to biopharma specifically. It is indeed home to 1,000+ life sciences startups, more than 1,200 public and private R&D labs and 12,000 life sciences researchers, and Europe’s largest hospital network.
PharmAI – Industry is Smartening Up to Potential of Artificial Intelligence
Artificial Intelligence (AI) has enormous potential in changing the delivery of health care and improving patient outcomes, with applications in pattern detection, patient monitoring, disease diagnosis and treatment selection. The rationale is that AI can be used to enhance the decision-making process, taking into account far more data than are available to physicians via conventional means.
Tracking the Power of Presenting at Biotech Showcase
For the first time, Informa Pharma Intelligence explores the achievements by Biotech Showcase presenting companies, delving into the deal-making activity that has occurred for companies who have presented at the conference in the last five years.